Judge Finds Company Did Not Mislead Investors About FDA Approval Prospects

( May 22, 2025, 4:30 PM EDT) -- NEW YORK — A federal judge in New York granted a biopharmaceutical company and its CEO’s motion to dismiss shareholders’ putative class action alleging the company and the CEO misled the market regarding its prospects of receiving U.S. Food and Drug Administration approval to market its lead product candidate, finding the shareholders failed to adequately allege falsity or raise a strong inference of scienter....